Preterm Birth and PROM Testing Market was valued at USD 1.5 billion in 2023 and is expected to reach USD 2.93 billion by 2032, growing at a CAGR of 7.7% over the forecast period 2024-2032.
This report offers key statistics on the market status of the leading Preterm Birth and PROM Testing market players and offers key trends and opportunities in the market. It delves into trends in the prescribing of diagnostic tests and treatments, as well as the volume and rate of adoption of this testing. The report also analyzes patterns of spending on health care, including from government, private, and out-of-pocket sources. It also covers technological innovations such as biomarker-based testing & AI-driven diagnostics as well as recent regulatory approvals impacting market dynamics. It offers a detailed analysis of regional market growth, highlighting differences in access among developed and emerging economies. Such insights allow stakeholders to grasp the significant market drivers, investment prospects, and other possible future growth opportunities. The global market for preterm birth and PROM testing is primarily driven by the increasing incidence of preterm births across the globe. There are an estimated 15 million premature births each year, according to the World Health Organization, and this number is increasing.
Market Dynamics
Drivers
Technological advancements, such as the development of predictive blood tests like PreTRM, enhance early detection and management of preterm births.
The integration of technology has greatly improved the early diagnosis and management of preterm births, which has ultimately reduced maternal and neonatal morbidity and mortality. An example is a blood test called PreTRM, which measures the levels of certain proteins to predict the risk of preterm delivery. The test, which can be performed between the 18th and 21st weeks of gestation, provides healthcare providers with the ability to take preventive measures, potentially decreasing the rate of preterm birth. In Australia, researchers at the University of Queensland have developed a rapid "nanoflower sensor" capable of detecting pregnancy complications, including risks of preterm birth, in the first trimester. Multiple cell biomarkers can be screened in blood samples, with an early detection accuracy of more than 90%, so that medical approaches can be initiated early. AI has also been incorporated into prenatal care to analyze the chances of preterm birth. Machine learning models, namely Support Vector Machines (SVMs), which were trained on data available immediately after the therapy, achieved an accuracy of 82% for assessing the risk of preterm birth, according to a study published in Scientific Reports. This method uses complex data patterns to detect pregnancies at risk and does this before a clinical diagnosis.
Additionally, for predicting the risk of imminent spontaneous preterm delivery, the PartoSure test has been designed to measure placental alpha microglobulin-1 (PAMG-1). Clinical studies have shown that this test provides a 97.4% negative predictive value for delivery within seven days among symptomatic women, offering a reliable tool for clinical decision-making. These breakthroughs in technology, which offer both high accuracy and early detection, play a key role in decreasing the rates of preterm birth and its subsequent complications. They also facilitate timely interventions, contributing to improved health outcomes for mothers and infants alike.
Restraint:
The high cost of advanced diagnostic tests and a shortage of skilled healthcare professionals limit accessibility, especially in low-resource settings.
These factors create significant growth challenges for the Preterm Birth and PROM Grid Test market as the high cost of advanced diagnostic tests limits its adoption, and there is a lack of skilled healthcare professionals. It said that there was a 22% shortage of doctors, 35% shortage of nurses, and 29% shortage of paramedical staff in primary and secondary healthcare under the state's Health Department, in a recent report by the Comptroller and Auditor General (CAG). The lack of trained staff inhibits the appropriate administration and ongoing interpretation of these specialty diagnostics. As a result, women who become pregnant may be inadequately, if at all, tested for conditions such as preterm birth and PROM, especially in rural and underserved communities, resulting in delayed interventions and poorer maternal and neonatal outcomes. Tackling these workforce shortages is essential to enhancing the accessibility and efficacy of diagnostic services across the region.
Opportunity:
The growing demand for point-of-care diagnostics, including home testing kits, offers convenient and accessible solutions for at-risk pregnant women.
The increasing need for point-of-care diagnostics, comprising home-based testing kits, provides a major opportunity in the Preterm Birth and PROM (Premature Rupturing of Membranes) Testing Market. Preterm birth, which is delivery before 37 weeks of gestation, happens in about 1 in 10 births in the United States and carries significant health risks for newborns. In recent years, new diagnostic tools have been developed for the early detection of the risk of preterm birth. For example, Researchers at the Ohio State University College of Nursing are developing a blood test that can determine the risk of preterm birth with up to 97.5% accuracy when taken before 20 weeks of pregnancy. The test is designed to be part of standard prenatal care, allowing clinicians to monitor and intervene as necessary, potentially cutting down on several preterm births and bettering health for both mothers and babies.
Moreover, the University of Queensland has developed a rapid "nanoflower sensor" capable of detecting neonatal problems, including preterm birth risks, in the first trimester by screening blood samples for cell biomarkers. This particular sensor has proven to be more than 90% effective at distinguishing pregnant women on the verge of experiencing pregnancy complications, which can lead to preventive medical intervention and can help avoid neonatal intensive care unit admissions and emergency interventions. Implementing point-of-care diagnostics into standard prenatal care may help reduce the risk of preterm birth. They help providers take action early to ensure that the health of both mothers and babies is at its best.
Challenge:
Navigating regulatory requirements and obtaining approvals for new testing technologies can be complex and time-consuming, hindering market penetration.
The regulatory requirements involved are a major challenge in the Preterm Birth and Premature Rupture of Membranes (PROM) testing market. Novel clinical diagnostics, including the PreTRM blood test produced by Sera Prognostics, promise to forecast the likelihood of preterm labor based on the concentration of particular proteins found within maternal blood. Though promising, these tests frequently do not have regulatory approval from leading organizations, such as the U.S. Food and Drug Administration (FDA), which can hinder broader implementation. For instance, the PreTRM test is currently not FDA-approved, though it is available for order by physicians and directly by women through Sera's website.
The regulatory approval pathway is complex and frequently long, often involving extensive clinical trials to prove safety and efficacy. This complexity can lead to delays in the rollout of new testing technologies to market, hampering timely access to healthcare providers and patients. The regulatory differences from country to country also make the task of achieving approval more difficult, as companies need to customize their respective approval strategies to meet these various standards. These obstacles may limit access to advanced diagnostic options, impacting the quality of prenatal care and outcomes. Partnership between diagnostic companies and the regulatory agencies is required to ensure the approval processes are not hindered but are aligned to make sure safety is paramount. All of these will be necessary to help ensure that such innovative testing solutions can get to market in a timely way, providing healthcare professionals with reliable tools to predict and manage preterm births effectively.
By Test Type
In 2023, the ultrasound segment accounted for 32% of the global preterm births and PROM testing market. This preference can be explained by multiple factors, in particular, the noninvasive character of US technology, its global availability, and its capability to reveal immediate images of fetal development and cervix microstructure changes, among others. Ultrasound assessments determine an individual's risk for preterm birth based on the length of her cervix and evaluate the health of the fetus. Pregnant women with a history of spontaneous preterm birth are recommended by the U.S. Preventive Services Task Force to have transvaginal ultrasound cervical length screening. As a result, this recommendation has led to an increasing use of ultrasound in prenatal care. Between 16 and 24 weeks of gestation, measurement of the cervical length by transvaginal ultrasound may, according to the American College of Obstetricians and Gynecologists, help in identifying women at increased risk for preterm birth. Moreover, new ultrasound technologies (3D and 4D imaging) have improved preterm birth risk prediction. These advancements enable greater characterization of fetal anatomy and improve the assessment of possible complications. Its relatively low cost and ease of use compared with other diagnostic procedures have led to the widespread use of ultrasound in both developed and developing countries.
By Application
In 2023, the preterm labor segment accounted for 41% of the market share, owing to the high prevalence of preterm birth across the globe. Preterm birth strikes 1 of every 10 babies born in the United States, according to the CDC. The March of Dimes reports that the preterm birth rate in the U.S. has increased for the third year in a row, reaching 10.5% in 2021. The Premature Rupture of Membranes (PROM) application segment is projected to grow at a significant rate. The Increasing recognition of PROM-associated complications and the availability of new diagnostic tests with higher accuracy are the major factors driving the growth of this segment. According to the American Journal of Obstetrics & Gynecology, PROM only happens in 3% of pregnancies, but it accounts for 30-40% of preterm deliveries. The increasing maternal age, along with rising associated risk factors (e.g., multiple pregnancies, infections, etc.) is driving the growth of this segment. Biomarker testing for PROM has advanced and, combined with the enhanced diagnostic accuracy seen with its use, has helped to improve outcomes in such women. For example, several non-invasive tests have been approved by the FDA for the detection of amniotic fluid proteins, and these tests have demonstrated high sensitivity and specificity in diagnosing PROM.
Regional analysis
In 2023, North America accounted for the highest share of the preterm birth and PROM testing market, with a share of around 38%. This leadership position is attributed to a mature healthcare infrastructure, high healthcare spending, and high focus on maternal and neonatal care in the region. The U.S. is leading the way in research and development in this area. The rate of preterm birth in the U.S. increased to 10.5% in 2021, a 4% increase from 2020, according to the National Center for Health Statistics. This persistent challenge has resulted in additional resources being allocated for research and prevention programs related to extreme or very preterm births. The National Institutes of Health (NIH) spent more than $500 million in 2022 on research related to preterm birth and its complications.
The Asia-Pacific region is expected to witness the fastest CAGR during the forecast period. This growth is mainly due to a large population base and improving healthcare infrastructure and awareness toward prenatal care in countries such as India and China. Over 60% of preterm births take place in Africa and South Asia, according to the World Health Organization, demonstrating the significant market potential for the solution. The National Health Commission has released several policies related to maternal and child health services in China, enabling efficient screening and management of high-risk pregnancy. Services like the Pradhan Mantri Surakshit Matritva Abhiyan have been introduced to offer free antenatal care to pregnant women in India, which is likely to accelerate the demand for preterm birth and PROM testing services.
Key Service Providers/Manufacturers
Hologic, Inc. (Rapid fFN Test, AmniSure ROM Test)
Abbott Laboratories (i-STAT System, ARCHITECT Clinical Chemistry)
Sera Prognostics Inc. (PreTRM Test)
CooperSurgical Inc. (ROM Plus, AmnioTest)
IQ Products (Actim PROM, Actim Partus)
Qiagen N.V. (PartoSure Test, AmniSure ROM Test)
Biosynex (PREMAQUICK, Amnioquick)
LifeCell International Pvt. Ltd. (Maternal Blood Test, Fetal Monitoring Services)
Clinical Innovations, LLC (ROM Plus, Koala Intrauterine Pressure Catheter)
NX Prenatal, Inc. (NeXosome Assay)
Medixbiochemica (Actim PROM, Actim Partus)
Medtronic (InSync III, Reveal LINQ)
Fisher & Paykel Healthcare Limited (Airvo 2, Optiflow)
FUJIFILM Holdings Corporation (SonoSite Ultrasound Systems, Synapse PACS)
Nonin Medical, Inc. (Onyx Vantage 9590, SenSmart Model X-100)
Getinge AB (Servo-n Neonatal Ventilator, Flow-c Anesthesia Machine)
General Electric Company (Voluson E10 Ultrasound, Corometrics 250cx Series)
Koninklijke Philips N.V. (EPIQ Ultrasound System, Avalon Fetal Monitor)
Promega Corporation (Maxwell RSC Instrument, GoTaq qPCR Master Mix)
Medical Predictive Science Corporation (Heart Rate Observation System, HeRO Duo)
Recent developments
In September 2024, Qiagen N.V. was granted FDA Approval for a new biomarker-based test predictive of risk for spontaneous preterm birth. The test examines a panel of protein biomarkers in maternal blood specimens.
In January 2025, Abbott Laboratories launched an AI-enabled ultrasound system for preterm birth risk analysis. The system employs machine learning algorithms to scrutinise cervical images and output risk scores.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 1.5 Billion |
| Market Size by 2032 | USD 2.93 Billion |
| CAGR | CAGR of 7.7% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Test Type (Ultrasound, Pelvic exam, Biochemical Markers {Interleukin (IL)-6, Corticotropin-Releasing Hormone (CRH), C-Reactive Protein (CRP), IL-1, IL-2, IL-8, TNF-a, Alpha-fetoprotein (AFP)}, Uterine Monitoring, Nitazine Test, Ferning Test, IGFBP Test, Pooling, PAMG-1 Immunoassay, Fetal Fibronectin (fFN), Others) • By Application (PROM, Preterm Labor, Chorioamnionitis) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Hologic Inc., Abbott Laboratories, Sera Prognostics Inc., CooperSurgical Inc., IQ Products, Qiagen N.V., Biosynex, LifeCell International Pvt. Ltd., Clinical Innovations LLC, NX Prenatal Inc., Medixbiochemica, Medtronic, Fisher & Paykel Healthcare Limited, FUJIFILM Holdings Corporation, Nonin Medical Inc., Getinge AB, General Electric Company, Koninklijke Philips N.V., Promega Corporation, Medical Predictive Science Corporation |
Ans. The projected market size for the Preterm Birth and PROM Testing Market is USD 2.93 billion by 2032.
Ans: The North American region dominated the Preterm Birth and PROM Testing Market in 2023.
Ans. The CAGR of the Preterm Birth and PROM Testing Market is 7.7% during the forecast period of 2024-2032.
Ans: Strategic Initiatives
Ans: The preterm labor Application segment dominated the Preterm Birth and PROM Testing Market.
Table of Content
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Market Demand and Prescription Trends (2023)
5.2 Testing Volume and Adoption Rates (2020-2032)
5.3 Healthcare Spending and Cost Distribution (2023)
5.4 Technological Advancements and Regulatory Approvals
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and supply chain strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Preterm Birth And PROM Testing Market Segmentation, By Test Type
7.1 Chapter Overview
7.2 Ultrasound
7.2.1 Ultrasound Market Trends Analysis (2020-2032)
7.2.2 Ultrasound Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Pelvic exam
7.3.1 Pelvic exam Market Trends Analysis (2020-2032)
7.3.2 Pelvic exam Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Biochemical Markers
7.4.1 Biochemical Markers Market Trends Analysis (2020-2032)
7.4.2 Biochemical Markers Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4.3 Interleukin (IL)-6
7.4.3.1 Interleukin (IL)-6 Market Trends Analysis (2020-2032)
7.4.3.2 Interleukin (IL)-6 Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4.4 Corticotropin-Releasing Hormone (CRH)
7.4.4.1 Corticotropin-Releasing Hormone (CRH) Market Trends Analysis (2020-2032)
7.4.4.2 Corticotropin-Releasing Hormone (CRH) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4.5 C-Reactive Protein (CRP)
7.4.5.1 C-Reactive Protein (CRP) Market Trends Analysis (2020-2032)
7.4.5.2 C-Reactive Protein (CRP) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4.6 IL-1, IL-2, IL-8, TNF-a
7.4.6.1 IL-1, IL-2, IL-8, TNF-a Market Trends Analysis (2020-2032)
7.4.6.2 IL-1, IL-2, IL-8, TNF-a Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4.7 Alpha-fetoprotein (AFP)
7.4.7.1 Alpha-fetoprotein (AFP) Market Trends Analysis (2020-2032)
7.4.7.2 Alpha-fetoprotein (AFP) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Uterine Monitoring
7.5.1 Uterine Monitoring Market Trends Analysis (2020-2032)
7.5.2 Uterine Monitoring Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Nitazine Test
7.6.1 Nitazine Test Market Trends Analysis (2020-2032)
7.6.2 Nitazine Test Market Size Estimates and Forecasts to 2032 (USD Billion)
7.7 Ferning Test
7.7.1 Ferning Test Market Trends Analysis (2020-2032)
7.7.2 Ferning Test Market Size Estimates and Forecasts to 2032 (USD Billion)
7.8 IGFBP Test
7.8.1 IGFBP Test Market Trends Analysis (2020-2032)
7.8.2 IGFBP Test Market Size Estimates and Forecasts to 2032 (USD Billion)
7.9 Pooling
7.9.1 Pooling Market Trends Analysis (2020-2032)
7.9.2 Pooling Market Size Estimates and Forecasts to 2032 (USD Billion)
7.10 PAMG-1 Immunoassay
7.10.1 PAMG-1 Immunoassay Market Trends Analysis (2020-2032)
7.10.2 PAMG-1 Immunoassay Market Size Estimates and Forecasts to 2032 (USD Billion)
7.11 Fetal Fibronectin (fFN)
7.11.1 Fetal Fibronectin (fFN) Market Trends Analysis (2020-2032)
7.11.2 Fetal Fibronectin (fFN) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.12 Others
7.12.1 Others Market Trends Analysis (2020-2032)
7.12.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Preterm Birth and PROM Testing Market Segmentation, By Application
8.1 Chapter Overview
8.2 PROM
8.2.1 PROM Market Trends Analysis (2020-2032)
8.2.2 PROM Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Preterm Labor
8.3.1 Preterm Labor Market Trends Analysis (2020-2032)
8.3.2 Preterm Labor Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Chorioamnionitis
8.4.1 Chorioamnionitis Market Trends Analysis (2020-2032)
8.4.2 Chorioamnionitis Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Preterm Birth And PROM Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.2.3 North America Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.2.4 North America Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.2.5 USA
9.2.5.1 USA Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.2.5.2 USA Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.2.6 Canada
9.2.6.1 Canada Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.2.6.2 Canada Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.2.7 Mexico
9.2.7.1 Mexico Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.2.7.2 Mexico Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.3 Europe
9.3.1 Eastern Europe
9.3.1.1 Trends Analysis
9.3.1.2 Eastern Europe Preterm Birth And PROM Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.1.3 Eastern Europe Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.3.1.4 Eastern Europe Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.3.1.5 Poland
9.3.1.5.1 Poland Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.3.1.5.2 Poland Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.3.1.6 Romania
9.3.1.6.1 Romania Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.3.1.6.2 Romania Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.3.1.7 Hungary
9.3.1.7.1 Hungary Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.3.1.7.2 Hungary Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.3.1.8 Turkey
9.3.1.8.1 Turkey Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.3.1.8.2 Turkey Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.3.1.9 Rest of Eastern Europe
9.3.1.9.1 Rest of Eastern Europe Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.3.1.9.2 Rest of Eastern Europe Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.3.2 Western Europe
9.3.2.1 Trends Analysis
9.3.2.2 Western Europe Preterm Birth And PROM Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.2.3 Western Europe Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.3.2.4 Western Europe Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.3.2.5 Germany
9.3.2.5.1 Germany Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.3.2.5.2 Germany Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.3.2.6 France
9.3.2.6.1 France Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.3.2.6.2 France Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.3.2.7 UK
9.3.2.7.1 UK Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.3.2.7.2 UK Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.3.2.8 Italy
9.3.2.8.1 Italy Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.3.2.8.2 Italy Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.3.2.9 Spain
9.3.2.9.1 Spain Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.3.2.9.2 Spain Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.3.2.10 Netherlands
9.3.2.10.1 Netherlands Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.3.2.10.2 Netherlands Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.3.2.11 Switzerland
9.3.2.11.1 Switzerland Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.3.2.11.2 Switzerland Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.3.2.12 Austria
9.3.2.12.1 Austria Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.3.2.12.2 Austria Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.3.2.13 Rest of Western Europe
9.3.2.13.1 Rest of Western Europe Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.3.2.13.2 Rest of Western Europe Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Preterm Birth And PROM Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.4.3 Asia Pacific Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.4.4 Asia Pacific Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.4.5 China
9.4.5.1 China Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.4.5.2 China Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.4.6 India
9.4.5.1 India Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.4.5.2 India Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.4.5 Japan
9.4.5.1 Japan Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.4.5.2 Japan Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.4.6 South Korea
9.4.6.1 South Korea Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.4.6.2 South Korea Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.4.7 Vietnam
9.4.7.1 Vietnam Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.2.7.2 Vietnam Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.4.8 Singapore
9.4.8.1 Singapore Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.4.8.2 Singapore Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.4.9 Australia
9.4.9.1 Australia Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.4.9.2 Australia Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.4.10 Rest of Asia Pacific
9.4.10.1 Rest of Asia Pacific Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.4.10.2 Rest of Asia Pacific Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.5 Middle East and Africa
9.5.1 Middle East
9.5.1.1 Trends Analysis
9.5.1.2 Middle East Preterm Birth And PROM Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.1.3 Middle East Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.5.1.4 Middle East Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.5.1.5 UAE
9.5.1.5.1 UAE Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.5.1.5.2 UAE Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.5.1.6 Egypt
9.5.1.6.1 Egypt Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.5.1.6.2 Egypt Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.5.1.7 Saudi Arabia
9.5.1.7.1 Saudi Arabia Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.5.1.7.2 Saudi Arabia Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.5.1.8 Qatar
9.5.1.8.1 Qatar Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.5.1.8.2 Qatar Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.5.1.9 Rest of Middle East
9.5.1.9.1 Rest of Middle East Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.5.1.9.2 Rest of Middle East Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.5.2 Africa
9.5.2.1 Trends Analysis
9.5.2.2 Africa Preterm Birth And PROM Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.2.3 Africa Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.5.2.4 Africa Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.5.2.5 South Africa
9.5.2.5.1 South Africa Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.5.2.5.2 South Africa Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.5.2.6 Nigeria
9.5.2.6.1 Nigeria Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.5.2.6.2 Nigeria Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.5.2.7 Rest of Africa
9.5.2.7.1 Rest of Africa Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.5.2.7.2 Rest of Africa Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Preterm Birth And PROM Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.6.3 Latin America Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.6.4 Latin America Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.6.5 Brazil
9.6.5.1 Brazil Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.6.5.2 Brazil Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.6.6 Argentina
9.6.6.1 Argentina Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.6.6.2 Argentina Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.6.7 Colombia
9.6.7.1 Colombia Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.6.7.2 Colombia Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
9.6.8 Rest of Latin America
9.6.8.1 Rest of Latin America Preterm Birth And PROM Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
9.6.8.2 Rest of Latin America Preterm Birth And PROM Testing Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10. Company Profiles
10.1 Hologic Inc.
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Products/ Services Offered
110.1.4 SWOT Analysis
10.2 Abbott Laboratories
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Products/ Services Offered
10.2.4 SWOT Analysis
10.3 Sera Prognostics Inc.
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Products/ Services Offered
10.3.4 SWOT Analysis
10.4 CooperSurgical Inc.
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Products/ Services Offered
10.4.4 SWOT Analysis
10.5 IQ Products
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Products/ Services Offered
10.5.4 SWOT Analysis
10.6 Qiagen N.V.
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Products/ Services Offered
10.6.4 SWOT Analysis
10.7 Biosynex
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Products/ Services Offered
10.7.4 SWOT Analysis
10.8 LifeCell International Pvt. Ltd.
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Products/ Services Offered
10.8.4 SWOT Analysis
10.9 Clinical Innovations LLC
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
10.10 NX Prenatal Inc.
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments:
By Test Type
Ultrasound
Pelvic exam
Biochemical Markers
Interleukin (IL)-6
Corticotropin-Releasing Hormone (CRH)
C-Reactive Protein (CRP)
IL-1, IL-2, IL-8, TNF-a
Alpha-fetoprotein (AFP)
Uterine Monitoring
Nitazine Test
Ferning Test
IGFBP Test
Pooling
PAMG-1 Immunoassay
Fetal Fibronectin (fFN)
Others
By Application
PROM
Preterm Labor
Chorioamnionitis
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The Medical Device Reprocessing Market size was estimated at USD 2.69 billion in 2023 and is expected to reach USD 9.63 billion by 2032 at a CAGR of 15.29% during the forecast period of 2024-2032.
The Surgical Sutures Market size was projected at USD 4.55 billion in 2023 and is anticipated to reach USD 7.18 billion by 2032 at a CAGR of 5.2% over the forecast period of 2024-2032.
Comprehensive Metabolic Panel Testing Market, valued at USD 11.18 Billion in 2023, is forecasted to grow at a 9.12% CAGR, reaching USD 24.48 Billion by 2032.
The Urinary Drainage Bags Market size was valued at USD 1.80 Billion in 2023, expected to reach USD 2.64 Billion by 2032, grow at a CAGR of 4.38%.
The Demineralized Bone Matrix (DBM) Market Size was valued at USD 1.29 billion in 2023 and is projected to reach USD 2.18 billion by 2032 with a growing CAGR of 5.98% Over the Forecast Period of 2024-2032.
The Healthcare Mobility Solutions Market Size was valued at USD 150.19 billion in 2023, and is expected to reach USD 1143.40 billion by 2032, and grow at a CAGR of 25.3% over the forecast period 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
